Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -85.15M | 87.01M | 64.45M | 18.77M | 4.21M |
| Total Depreciation and Amortization | 1.57M | 1.51M | 1.44M | 1.36M | 1.30M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.48M | 31.09M | 32.94M | 37.72M | 37.73M |
| Change in Net Operating Assets | -2.10M | -12.11M | -10.04M | -2.82M | 1.62M |
| Cash from Operations | -57.20M | 107.51M | 88.79M | 55.04M | 44.86M |
| Capital Expenditure | -1.06M | -1.55M | -1.71M | -1.96M | -1.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.06M | -1.55M | -1.71M | -1.96M | -1.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 291.00K | 288.00K | 75.71M | 231.64M | 235.22M |
| Repurchase of Common Stock | -381.22M | -378.90M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 139.00K | 139.00K | 0.00 | -130.00K | -195.00K |
| Cash from Financing | -380.79M | -378.47M | 75.71M | 231.51M | 235.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -439.04M | -272.52M | 162.79M | 284.59M | 278.34M |